T1	Disease 354 362	AD + CVD
T4	Disease 272 280	dementia
T5	Disease 304 323	Alzheimer's disease
T6	Disease 329 352	cerebrovascular disease
T7	Disease 394 402	dementia
T8	Disease 482 490	dementia
T9	Disease 1281 1289	AD + CVD
T10	Disease 2727 2729	AD
T11	Disease 2706 2725	Alzheimer's disease
*	Equiv T11 T10
T12	Disease 2828 2851	Cerebrovascular disease
T13	Disease 2853 2856	CVD
*	Equiv T12 T13
T14	Disease 2923 2925	AD
T15	Disease 2929 2938	AD + CVD,
T16	Modification 3508 3522	citrullination
T17	Modification 3527 3540	carbamylation
T18	Modification 3770 3783	Carbamylation
T19	Modification 4277 4291	Citrullination
T20	Modification 4461 4474	carbamylation
T22	Disease 4940 4948	AD + CVD
T21	Disease 4920 4928	dementia
T23	Disease 5759 5767	AD + CVD
T24	Disease 5991 6009	multiple sclerosis
T25	Disease 6011 6013	MS
*	Equiv T24 T25
T26	Disease 6104 6112	AD + CVD
T27	Modification 6173 6186	citrullinated
T28	Modification 6191 6203	carbamylated
T29	FractionationMethod 7168 7250	ultracentrifugation-electrostatic repulsion hydrophilic interaction chromatography
T31	FractionationFraction 7316 7323	soluble
T32	FractionationFraction 7328 7338	aggregated
T33	FractionationFraction 7467 7474	soluble
T34	FractionationFraction 7479 7489	aggregated
T2	Disease 107 156	Alzheimer's disease with cerebrovascular disease.
T3	FactorValue 107 155	Alzheimer's disease with cerebrovascular disease
T30	Disease 7520 7528	AD + CVD
T35	Modification 7645 7657	carbamylated
T36	Disease 7767 7775	AD + CVD
T37	Disease 8288 8296	AD + CVD
T38	Organism 8346 8351	human
T39	OrganismPart 8367 8387	middle temporal lobe
T40	OrganismPart 8389 8400	BA21 region
T41	FactorValue 8288 8296	AD + CVD
T42	Disease 8575 8583	AD + CVD
T43	SupplementaryFile 8747 8756	Table S1.
T44	NumberOfBiologicalReplicates 8757 8762	Three
T45	OrganismPart 9016 9033	BA21 brain region
T46	FractionationFraction 11406 11413	Soluble
T47	FractionationFraction 11418 11429	particulate
T48	CleavageAgent 12063 12070	trypsin
T49	CleavageAgent 13932 13939	trypsin
T50	GradientTime 14640 14646	72-min
T51	GradientTime 14793 14799	60-min
T52	Instrument 15295 15309	Orbitrap Elite
T53	ReductionReagent 11897 11900	DTT
T54	MS2MassAnalyzer 16297 16305	Orbitrap
T55	AcquisitionMethod 16698 16719	ten most intense ions
T56	PrecursorMassTolerance 17184 17190	10 ppm
T57	PrecursorMassTolerance 17195 17202	0.05 Da
T58	Modification 17294 17326	Carbamidomethylation of cysteine
T59	Disease 18152 18160	AD + CVD
T60	Modification 18318 18331	citrullinated
T61	Modification 18342 18354	carbamylated
T62	Disease 18936 18944	AD + CVD
T63	SupplementaryFile 20411 20421	Figure S1a
T64	SupplementaryFile 20445 20454	Dataset 2
T65	SupplementaryFile 20593 20603	Figure S1b
T66	FractionationFraction 20623 20630	soluble
T67	Disease 20666 20674	AD + CVD
T68	IonizationType 16197 16230	Spray nanoelectrospray ion source
